

**PAPERS READ BEFORE THE ANNUAL MEETING OF THE SOCIETY OF SURGICAL ONCOLOGY,
LONDON, APRIL 27 TO APRIL 30, 1987—PART I**

- At Last—Worldwide Agreement on the Staging of Cancer: Presidential Address** 1235
Robert V. P. Hutter, MD, Livingston, NJ
- James Ewing, MD: Contemporary Oncologist Exemplar: The James Ewing Lecture** 1240
LaSalle D. Leffall, Jr, MD, Washington, DC
- The Significance of Local Control in the Primary Treatment of Breast Cancer:
Lucy Wortham James Clinical Research Award** 1244
John Hayward, FRCS, Maira Caleffi, MD, London
The results of radical mastectomy were better than those of wide excision in patients with smaller tumors (T1).
- Identification of Patients at High Risk for Local Recurrence After
Conservative Surgery and Radiation Therapy for Stage I or II Breast Cancer** 1248
Robert T. Osteen, MD; James L. Connolly, MD; Abram Recht, MD; Barbara Silver; Stuart J. Schnitt, MD; Jay R. Harris, MD, Boston
More intraductal disease than was evident grossly or by frozen section was associated with increased local recurrence.
- Metastases in Small Lymph Nodes From Colon Cancer** 1253
Lemuel Herrera-Ornelas, MD, MA (EXP PATH), Buffalo; Jorge Justiniano, MD, Mayaguez, Puerto Rico;
Nieva Castillo, MD; Nicholas J. Petrelli, MD; Jaroslav P. Stulc, MD; Arnold Mittelman, MD, Buffalo
Small lymph nodes (<5 mm) from colorectal cancer specimens are frequently the site of metastases.
- Chromosomal Changes in Soft-Tissue Sarcomas: A New Diagnostic Parameter** 1257
Constantine P. Karakousis, MD, PhD; Paola Dal Cin, PhD; Claude Turc-Carel, MD;
Janusz Limon, MD; Avery A. Sandberg, MD, Buffalo
Identification of specific chromosome changes in sarcomas may provide new diagnostic criteria for these tumors.
- The Value of Colonoscopic Surveillance After Curative Resection
for Colorectal Cancer or Synchronous Adenomatous Polyps** 1261
Goran Carlsson, MD, PhD; Nicholas J. Petrelli, MD; Hector Nava, MD; Lemuel Herrera, MD; Arnold Mittelman, MD, Buffalo
In patients with colorectal cancer, colonoscopy preoperatively and postoperatively disclosed a high incidence of synchronous and metachronous neoplasms.
- The Prognostic Significance of Natural Killer
Cytotoxicity in Patients With Colorectal Cancer** 1264
Paul Ian Tartter, MD; Bryan Steinberg; Deborah M. Barron; Giorgio Martinelli, PhD, New York
Low levels of natural killer cell cytotoxicity were associated with a poor prognosis in patients with colorectal cancer.
- Enhancement of Tumor Blood Flow and Tumorcidal Effect of Doxorubicin by
Intraportal Epinephrine in Experimental Liver Metastasis** 1269
Norman D. Bloom, MD; Ellen Kroop; Manijeh Sadjadi, MD; Roger Jacobs, PhD;
Geetha Ramaswamy, MD; Norman B. Ackerman, MD, PhD, New York
Epinephrine enhanced blood flow and tumorcidal chemotherapeutic effect to experimental liver tumors.
- Regional Infusion for Colorectal Hepatic Metastases:
A Randomized Trial Comparing the Hepatic Artery With the Portal Vein** 1273
John M. Daly, MD; Nancy Kemeny, MD; Elin Sigurdson, MD, PhD; Paula Oderman, RN; Arleen Thom, MD, New York
With a hepatic artery infusion, four of eight patients responded, but none of 11 responded to a portal vein infusion.

The **ARCHIVES OF SURGERY** (ISSN 0004-0010) is published monthly by the American Medical Association, 535 N Dearborn St, Chicago, IL 60610, and is an official publication of the Association. Second-class postage paid at Chicago, IL 60610 and at additional mailing office.

SUBSCRIPTION RATES—The subscription rates for the Archives of Surgery are as follows: for members of the AMA, \$1.50 included in the annual membership dues; for nonmembers, \$38 for one year, \$68 for two years in the United States and US possessions; all other countries, one year, \$50; two years, \$92 (add \$15 surcharge to each one-year subscription, \$30 for two years for air delivery to the United Kingdom, Europe, Bangladesh, India, Nepal, or Sri Lanka). Special yearly rates to residents and medical students in the United States and US possessions, one year, \$19; two years, \$34. Rates for subscriptions for delivery to Australia, Japan, New Zealand, or South Korea are available through respective exclusive agents. Address all

subscription communications to the American Medical Association, Circulation and Fulfillment Division, 535 N Dearborn St, Chicago, IL 60610. Phone: (312) 280-7154.

CHANGE OF ADDRESS—POSTMASTER, send all address changes to Caryl L. Wertheimer, Director of Fulfillment, 535 N Dearborn St, Chicago, IL 60610. Notification of address change must be made at least six weeks in advance, include both old and new addresses, a recent mailing label, and your new zip code.

ADVERTISING PRINCIPLES: Each advertisement in this issue has been reviewed and complies with the principles governing advertising in AMA scientific publications. A copy of these principles is available on request. The appearance of advertising in AMA publications is not an AMA guarantee or endorsement of the product or the claims made for the product by the manufacturer.

CONTENTS—Continued

Reliability of Implantable Central Venous Access Devices in Patients With Cancer 1280
Gregory V. Stanislav, MD; Robert J. Fitzgibbons, Jr, MD; Robert T. Bailey, Jr, PharmD;
James A. Mailliard, MD; P. Steven Johnson, MD; John B. Feole, Omaha
Complications with implantable central venous access devices were less than with Hickman catheters.

Proton Magnetic Resonance Spectral Patterns of Metastasizing and Nonmetastasizing Human Colon Cancers 1284
Wei Chen, MD; James W. Frazer, PhD; Lawrence Dennis, PhD; Charles M. McBride, MD; Arthur W. Boddie, Jr, MD, Houston
Specimens of colon cancer that had metastasized had somewhat different spectral features from those that had not spread.

Local Recurrence in Adult Soft-Tissue Sarcoma: A Randomized Trial of Brachytherapy 1289
Murray F. Brennan, MD; Basil Hilaris, MD; Man H. Shiu, MD; Joseph Lane, MD;
Gordon Magill, MD; Claudia Friedrich; Steven I. Hajdu, MD, New York
Brachytherapy following resection of soft-tissue sarcomas significantly decreased the rate of local recurrence.

Challenges in the Treatment of Childhood Fibromatosis 1296
Bhaskar N. Rao, MD; Marc E. Horowitz, MD; David M. Parham, MD; Erlinda E. Etcubanas, MD; Irvin D. Fleming, MD;
Charles B. Pratt, MD; H. Omar Hustu, MD; Alexander A. Green, MD; Larry E. Kun, MD, Memphis
Complete resection produces the most satisfactory outcome in pediatric patients with fibromatosis (desmoid tumors).

Estrogen Receptor Protein of Breast Cancer in Patients With Positive Nodes: High Recurrence Rates in the Postmenopausal Estrogen Receptor–Negative Group 1303
David W. Kinne, MD, New York; John A. Butler, MD, Los Angeles; Marek Kimmel, PhD, New York;
Betty J. Flehinger, PhD, Yorktown Heights, NY; Celia Menendez-Botet, PhD, Morton Schwartz, PhD, New York
Postmenopausal women with estrogen receptor–positive tumors and axillary spread fared better than did those with estrogen receptor–negative tumors.

The Mechanism of Hormone-Sensitive Breast Cancer Progression on Antiestrogen Therapy: Implications for Treatment and Protocol Planning 1311
Rodney F. Pommier, MD; Eugene A. Woltering, MD; Edward J. Keenan, PhD; William S. Fletcher, MD, Portland, Ore
Patients whose disease progressed while receiving tamoxifen were found to have increased levels of estrone, estradiol, and dehydroepiandrosterone.

Does Radical Mastectomy Still Have a Place in the Treatment of Primary Operable Breast Cancer? 1317
William A. Maddox, MD; John T. Carpenter, Jr, MD; Henry T. Laws, MD; Seng-Jaw Soong, PhD;
Gretchen Cloud, MS, Birmingham, Ala; Charles M. Balch, MD, Houston; Marshall M. Urist, MD, Birmingham, Ala
Patients with more advanced local disease seemed to benefit from a more comprehensive operation.

Hyperthermic Pelvic Isolation-Perfusion in the Treatment of Refractory Pelvic Cancer 1321
Alan Wile, MD, Michael Smolin, MD, Orange, Calif
An isolation-perfusion technique using hyperthermia and chemotherapy with occlusion and cannulation from the groin provided palliation in 75% of patients.

Inflammatory Breast Carcinoma: Effective Multimodal Approach 1329
Gary V. Burton, MD; Edwin B. Cox, MD; George S. Leight, Jr, MD; Leonard R. Prosnitz, MD;
James D. Iglehart, MD; Gregg A. Olsen, MD; Hilliard F. Seigler, MD; Lowell L. Hart, MD, Durham, NC
Combined chemotherapy and irradiation with operation produced median overall survival of 18 months or more.

Therapy of Peritoneal Carcinomatosis of Human Colon Cancer Xenografts With Yttrium 90–Labeled Anti–Carcinoembryonic Antigen Antibody ZCE025 1333
David M. Hyams, MD, Jose M. Esteban, MD, Duarte, Calif; Charles P. Lollo, PhD, San Diego;
Barbara G. Beatty, PhD, J. David Beatty, MD, Duarte, Calif
The tumor burden was decreased in animals treated with this radioactively labeled antibody.

Prognosis for Recurrent Stage I Malignant Melanoma 1338
Douglas S. Reintgen, MD; Robin Vollmer, MD; C. Y. Tso, PhD; Hilliard F. Seigler, MD, Durham, NC
Six factors to predict prognosis were identified in patients with recurrence.

Cytologic Diagnosis of Occult Breast Lesions Using Stereotaxic Needle Aspiration: A Preliminary Report 1343
Kambiz Dowlatshahi, MD; Peter M. Jochik, MD; Robert Schmidt, MD; Marluce Bibbo, MD; Peter J. Dawson, MD, Chicago
This technique provided cytologic diagnosis by aspiration in 11 of 12 breast cancers in 84 patients.

Influence of the Extent of Resection on Survival After Curative Treatment of Gastric Carcinoma: A Retrospective Multivariate Analysis 1347
Man H. Shiu, MD; Eric Moore, MD; Melinda Sanders, MD; Andrew Huvos, MD; Berton Freedman, MPH;
James Goodbold, PhD; Srichai Chaiyaphruk, MD; Rob Wesdorp, MD; Murray F. Brennan, MD, New York
Microscopic tumor at margins, inadequate lymphadenectomy, and total gastrectomy indicated a poor prognosis.

Prognosis in Occult Thymomas in Myasthenia Gravis Following Transcervical Thymectomy 1352
A. E. Papatestas, MD; Jason Pozner, MD; Gabriel Jenkins, MD; Peter Kornfeld, MD; Raymond J. Matta, MD, New York
Occult thymomas were smaller, less invasive, and associated with a higher remission rate.

REGULAR DEPARTMENTS

Calendar 1234

Instructions for Authors 1233

Index to Advertisers 1221